Page 367 - Read Online
P. 367

Nedogoda et al. Vessel Plus 2018;2:37  I  http://dx.doi.org/10.20517/2574-1209.2018.36                                                Page 9 of 9

               19.  Yusuf S, Bosch J, Dagenais G, Zhu J, Xavier D, et al. Cholesterol lowering in intermediate-risk persons without cardiovascular disease.
                   N Engl J Med 2016;374:2021-31.
               20.  Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, et al. Rosuvastatin to prevent vascular events in men and women with
                   elevated C-reactive protein. N Engl J Med 2008;359:2195-207.
               21.  Roberts ER, Green D, Kadam UT. Chronic condition comorbidity and multidrug therapy in general practice populations: a cross-
                   sectional linkage study. BMJ Open 2014;4:e005429.
               22.  American Diabetes Association. Standards of medical care in diabetes 2017: summary of revisions. Diabetes Care 2017;40:S4-5.
               23.  Doupis J, Papanas N, Cohen A, McFarlan L, Horton E. Pulse wave analysis by applanation tonometry for the measurement of arterial
                   stiffness. Open Cardiovasc Med J 2016;31:188-95.
               24.  Van Bortel LM, De Backer T, Segers P. Standardization of arterial stiffness measurements make them ready for use in clinical practice.
                   Am J Hypertens 2016;29:1234-6.
               25.  Cuende JI, Cuende N, Calaveras-Lagartos J. How to calculate vascular age with the SCORE project scales: a new method of
                   cardiovascular risk evaluation. Eur Heart J 2010;31:2351-8.
               26.  Briasoulis A, Agarwal V, Valachis A, Messerli FH. Antihypertensive effects of statins: a meta-analysis of prospective controlled studies.
                   J Clin Hypertens (Greenwich) 2013;15:310-20.
               27.  Kario K. Orthostatic hypertension-a new haemodynamic cardiovascular risk factor. Nat Rev Nephrol 2013;9:726-38.
               28.  Ionescu DD; PREFER Investigators. Antihypertensive efficacy of perindopril 5-10 mg/day in primary health care: an open-label,
                   prospective, observational study. Clin Drug Investig 2009;29:767-76.
               29.  Fennessy PA, Campbell JH, Mendelsohn FA, Campbell GR. Angiotensin-converting enzyme inhibitors and atherosclerosis: relevance of
                   animal models to human disease. Clin Exp Pharmacol Physiol 1996;23:S30-2.
               30.  Koz C, Baysan O, Yokusoglu M, Uzun M, Yildirim M, et al. The effects of perindopril on aortic elasticity and inflammatory markers in
                   hypertensive patients. Med Sci Monit 2009;15:PI41-5.
   362   363   364   365   366   367   368   369   370   371   372